Antineoplastické účinky simvastatínu u experimentálnej rakoviny prsníka

English version

Autoři: P. Kubatka ^1,2; K. Žihlavniková ¹; K. Kajo ³; M. Péč ^1,2; N. Stollárová ²; B. Bojková ⁴; M. Kassayová ⁴; P. Orendáš ⁴
Působiště autorů: Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic ¹; Department of Biology and Ecology, Faculty of Education, Catholic University in Ružomberok, Slovak Republic ²; Department of Pathological Anatomy, Jessenius Faculty of Medicine, Comenius University, Martin, and BB Biocyt, Diagnostic Centre, Ltd., Banská Bystrica, Slovak Republic ³; Department of Animal Physiology, Institute of Biological and Ecological Sciences, Science Faculty, P. J. Šafárik University, Košice, Slovak Republic ⁴
Vyšlo v časopise: Klin Onkol 2011; 24(1): 41-45
Kategorie: Původní práce

Souhrn

Východiská:
Statíny (inhibítory 3-hydroxy-3-metylglutaryl koenzým A reduktázy) predstavujú látky s dobre dokumentovanými terapeutickými a preventívnymi účinkami u kardiovaskulárnych ochorení. V predklinických štúdiách statíny preukázali tumor-supresívne účinky u viacerých typov neoplázií vrátane rakoviny prsníka.

Materiál a metódy:
V tejto štúdii sme hodnotili antineoplastický účinok simvastatínu v chemoprevencii N-metyl-N-nitrozoureou – indukovanej mamárnej karcinogenézy u samíc potkanov. Farmakum bolo aplikované v potrave vo dvoch koncentráciách – 18 mg/ kg (SIMVA 18) a 180 mg/ kg (SIMVA 180).

Výsledky:
Po dlhodobej aplikácii simvastatínu sme na konci pokusu vyhodnotili základné parametre experimentálnej karcinogenézy. Simvastatín v skupine SIMVA 180 signifikantne znížil frekvenciu nádorov o 80,5 % a incidenciu nádorov o 58,5 % v porovnaní s kontrolou. Simvastatín v tej istej skupine zvierat nesignifikantne znížil priemerný objem nádorov o 23,5 % a nesignifikantne predĺžil latenciu o 14,5 dňa v porovnaní s kontrolnými zvieratami. U simvastatínu podávaného v nižšej dávke sme nepozorovali antineoplastické účinky. Simvastatín v oboch liečených skupinách signifikantne znížil sérové hladiny triacylglycerolov a VLDL-cholesterolu v porovnaní s kontrolnými zvieratami. V porovnaní s kontrolami sme v skupinách SIMVA 18 a SIMVA 180 pozorovali signifikantný nárast príjmu potravy u zvierat. Signifikantné zmeny prírastku telesnej hmotnosti medzi skupinami so simvastatínom a kontrolnou skupinou neboli zistené.

Záver:
Táto štúdia je prvou zmienkou o simvastatíne použitom v experimentálnej mamárnej karcinogenéze in vivo.

Kľúčové slová:
mamárna karcinogenéza – potkan – chemoprevencia – simvastatín

Zdroje

1. Rao S, Lowe M, Herliczek TW et al. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998; 17(18): 2393–2402.

2. Denoyelle C, Vasse M, Korner M et al. Cerivastatin, an inhibitor of HMGCoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22(8): 1139–1148.

3. Jiang Z, Zheng X, Lytle RA et al. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem 2004; 89(1): 168–178.

4. Cafforio P, Dammacco F, Gernone A et al. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26(25): 883–891.

5. Weis M, Heeschen C, Glassford AJ et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105(6): 739–745.

6. Park HJ, Kong D, Iruela-Arispe L et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91(2): 143–150.

7. Nübel T, Dippold W, Kleinert H et al. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 2004; 18(1): 140–142.

8. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol 2000; 86(2): 83–91.

9. Kusama T, Mukai M, Iwasaki T et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122(2): 308–317.

10. Collisson EA, Kleer C, Wu M et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003; 2(10): 941–948.

11. Narisawa T, Fukaura Y, Terada K et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994; 15(9): 2045–2048.

12. Tatsuta M, Iishi H, Baba M et al. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 1998; 77(4): 581–587.

13. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–1622.

14. Cauley JA, Zmuda JM, Lui LY et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 2003; 12(8): 749–756.

15. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352(21): 2184–2192.

16. Blais L, Desgagné A, LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160(15): 2363–2368.

17. Shannon J, Tewoderos S, Garzotto M et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162(4): 318–325.

18. Katz MS, Minsky BD, Saltz LB et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62(5): 1363–1370.

19. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84(7): 886–891.

20. Minden MD, Dimitroulakos J, Nohynek D et al. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 2001; 40(5–6): 659–662.

21. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000; 5(2): 187–200.

22. Narisawa T, Morotomi M, Fukaura Y et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87(8): 798–804.

23. Lubet RA, Boring D, Steele VE et al. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res 2009; 2(2): 161–167.

24. Blanco-Colio LM, Villa A, Ortego M et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161(1): 17–26.

25. Hindler K, Cleeland CS, Rivera E et al. The role of statins in cancer therapy. Oncologist 2006; 11(3): 306–315.